STAT+: NYU professors who defended vaping didn’t disclose ties to Juul, documents show
WASHINGTON – Two New York University professors collaborated directly with executives of the vaping company…
Category: STAT+
STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity…
STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Senate drug shortage bill would pay hospitals bonuses for good contracting practices
WASHINGTON — The Senate Finance Committee has drafted a bipartisan bill to mitigate drug shortages…
STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill
Amgen said Thursday that it will no longer develop an early-stage obesity pill, and will…
STAT+: Lawmakers unlikely to permanently extend telehealth flexibilities this year
WASHINGTON — Members of Congress appear poised to advance another short-term extension of pandemic-era telehealth…
STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug
In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious…
STAT+: Health economist marks up UnitedHealth CEO’s Senate hearing on the Change Healthcare cyberattack
For lawmakers on both sides of the aisle, Wednesday’s congressional hearings about the Change Healthcare…
STAT+: Novo Nordisk defends Ozempic price in face of Senate scrutiny
Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy…
.jpg)
STAT+: Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Novartis’ $3 billion MorphoSys boondoggle
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: BridgeBio spins out oncology company as it focuses on heart drug
BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it…
STAT+: Novartis extends radiopharma plans with $1 billion acquisition
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even…
STAT+: Transcarent, Glen Tullman’s health tech unicorn, raises $126 million
Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman,…
STAT+: Biological clocks could be the key to longer, healthier lives. But scientists don’t yet agree on what ‘aging’ is
It’s no secret that a lucky few seem to glide into old age, the years…
STAT+: DEA reverses a policy to avert morphine shortages
WASHINGTON — The Drug Enforcement Agency is reversing a regulation that had been expected to…
STAT+: Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chief
Three years ago, Moderna, flush with cash from Covid vaccine sales, announced it would start…
STAT+: CVS went hard after Medicare Advantage patients, now it’s retreating
CVS Health got walloped at the outset of 2024 as older adults in its Medicare…
STAT+: Lawmakers grill UnitedHealth CEO on Change cyberattack. ‘Your company let the country down’
On Wednesday, UnitedHealth CEO Andrew Witty appeared before Congress to answer for what lawmakers called…
STAT+: Experimental gene therapy seems to alleviate skeletal defects tied to rare inherited disease, study shows
LONDON — In 2021, a team of Italian researchers reported that an experimental gene therapy…
STAT+: To regrow blood vessels after heart attack, a little transplant of mitochondria goes a long way in mice
Blood vessels in the legs or heart sustain considerable damage when they are narrowed by…
STAT+: Pharmalittle: We’re reading about FTC fighting ‘junk’ patents, Pfizer direct-to-consumer plans, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Mount Sinai’s responses to STAT’s questions about the Living Brain Project
As part of its reporting on Mount Sinai and the Living Brain Project, STAT sent…
STAT+: Brain biopsies on ‘vulnerable’ patients at Mount Sinai set off alarm bells at FDA, documents show
NEW YORK — By the time Peter Bauman considered deep brain stimulation, he was desperate….
STAT+: In a big reversal, Walmart to shut down medical clinics and online care
Walmart had grand ambitions, back in 2019, to grow a network of cheaper primary care…
STAT+: FTC issues more warnings to drug companies for ‘junk’ patent listings
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it…
STAT+: Akili to lay off 46% of its staff, explore strategic options amid sluggish sales
Akili Interactive on Tuesday announced it will lay off 46% of its staff and evaluate…
STAT+: Former MIT biologist David Sabatini, forced out after sexual harassment accusations, to lead new Boston team
Former MIT and Whitehead Institute star biologist David Sabatini, who lost his lofty positions after…
STAT+: Pharmalittle: We’re reading about a Medicare price-negotiation ruling, pharma’s slipping reputation, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Eli Lilly raises earnings guidance as Zepbound sales beat expectations
Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of…
STAT+: Biden cybersecurity plan for hospitals entails carrots first, then sticks, health official says
WASHINGTON — The Biden administration’s plan to improve cybersecurity at hospitals starts off with incentives,…
STAT+: Pharma’s reputation with patient groups is sliding again thanks to prices and shortages
The pharmaceutical industry saw its reputation slip last year among patient advocacy groups thanks to…
STAT+: FDA finalizes plan to regulate some lab-developed tests
The Food and Drug Administration will start actively regulating tests developed in laboratories, with some…
STAT+: Activist investor Alex Denner, Bioverativ shareholder reach tentative settlement in insider trading case
A tentative settlement has been reached in a long-running shareholder lawsuit that accused health care…
STAT+: Biden administration boosts some Medicaid payments to match commercial rates
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
.jpg)
STAT+: House bill aimed at Chinese biotechs is advancing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion
Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of…
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs…
STAT+: AI is becoming the exclusive province of academic medicine. A new initiative aims to change that
In Kingman, Ariz., a windswept city of 35,000 at the eastern edge of the Mojave…
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for…
STAT+: Momentum builds for House bill cracking down on Chinese biotechs
WASHINGTON — A House committee plans to mark up next month legislation that would restrict…
STAT+: Another hospital sues MultiPlan, alleging scheme to ‘suppress’ payments
MultiPlan is facing a new class action lawsuit that alleges the company and large health…
STAT+: Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Vertex offers limited access to a cystic fibrosis drug in South Africa — and may undercut a court case
After months of sustained criticism, Vertex Pharmaceuticals reached an agreement to provide a pricey cystic…
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
University of Washington professor David Baker has made a name for himself by borrowing computer…
STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future
Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last…